Dr. Nicoletta Colombo breaks down KEYNOTE B96 showing Keytruda plus paclitaxel, with or without Avastin, improves survival in platinum-resistant ovarian cancer. The phase 3 KEYNOTE B96 trial showed ...

During the Miami Breast Cancer Conference, CURE discussed ADCs with Dr. Kevin Kalinsky.

Dr. Will Parsons, of Texas Children’s, discusses evolving therapies, survivorship clinics and tools like Passport For Care for long-term cancer care.

KEYNOTE-B15 compared perioperative enfortumab vedotin plus pembrolizumab against neoadjuvant cisplatin-based chemotherapy in cisplatin-eligible MIBC, using event-free survival as the primary endpoint.

Dr. Will Parsons, of Texas Children’s, discusses evolving therapies, survivorship clinics and tools like Passport For Care for long-term cancer care. For a child diagnosed with cancer, cure is the ...

No matter how hard this is, I still recommend clinical trials. Not as a last resort, but as an important option when weighing treatment choices. I don’t know what choice I’ll make, but I’m thankful ...

Faculty at the University of Milan-Bicocca and Director of the Gynecologic Oncology Program at the European Institute of Oncology in Milan.

Dr. Matthew Galsky spoke with CURE about the KEYNOTE-B15 trial results and their potential impact on muscle-invasive bladder cancer care. At the 2026 ASCO Genitourinary Cancers Symposium, the ...

The blood–brain barrier functions as an evolutionarily optimized vascular “filter,” permitting limited penetration of small molecules like temozolomide while effectively excluding most biologics from ...

Friedberg noted that chemotherapy combined with an antibody remains a recommended treatment for patients with advanced-stage ...

Dr. Hope Rugo explains how antibody-drug conjugates like Datroway and Trodelvy are shifting the treatment landscape for ...

ImmunityBio’s sBLA targets BCG-unresponsive papillary NMIBC without CIS, complementing the existing U.S. approval for CIS ...